Business
Why the Telix (ASX:TLX) share price is surging 8%
Telix Pharmaceuticals Ltd (ASX: TLX) shares are rocketing higher this morning after the company announced the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for a prostate cancer imaging product. In early morning trade, the Telix share price is trading 8.1% higher at $3.07.
NDA approval
Investors are driving up the Telix share price today after news that the FDA has accepted the company’s NDA for TLX591-CDx (kit for the preparation of Ga-PSMA-11). The prostate cancer imaging product is a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). It uses a Positron Emission Tomography (PET) to scan for the disease.
Telix’s NDA submission for its prostate cancer imaging…
-
Noosa News5 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
General16 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General19 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique
-
Noosa News18 hours agoPeak body calls for national oversight of ADHD diagnoses during growth trend as GP powers expand